$Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

Pharmaceutical company bonds, the most expensive in the U.S. corporate credit market, face rating cuts after a buyout spree to replace expiring patents more than doubled their debt to $270 billion from 2006.


Drugmakers Risk Downgrades




By John Detrixhe and Shannon Pettypiece

April 19 (Bloomberg)


http://www.bloomberg.com/apps/news?pid=20601087&sid=a_vg1RqzyK3M&pos=7

Pharmaceutical company bonds, the most expensive in the U.S. corporate credit market, face rating cuts after a buyout spree to replace expiring patents more than doubled their debt to $270 billion from 2006.